Prognostic value of platelet-to-lymphocyte ratio in prostate cancer patients:a meta analysis / 现代泌尿外科杂志
Journal of Modern Urology
;
(12): 50-58, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-1005465
ABSTRACT
【Objective】 To evaluate the value of platelet-to-lymphocyte ratio (PLR) in the prognosis of prostate cancer. 【Methods】 Relevant studies were searched in CNKI, Wanfang, CBM, VIP, PubMed, Web of Science, Cochrane Library and Embase databases from inception to Dec.2021. The literature was screeded, data were extracted, and the quality was evaluated according to the inclusion and exclusion criteria. A meta-analysis by using the hazard risk (HR) and 95% confidence interval (CI) was adopted to assess the prognostic value of PLR. The data were analyzed with STATA 16.0 software. 【Results】 A total of 10 studies were included, involving 1 802 patients. For patients with high level of PLR, the overall survival (OS) (HR=1.70, 95%CI1.25-2.30, P=0.001) and disease-free survival (DFS)(HR=1.44, 95%CI1.15-1.81, P=0.002) were significantly shorter. 【Conclusion】 PLR is an independent risk factor affecting the long-term prognosis of prostate cancer patients. Pretreatment detection of PLR is meaningful in determining the prognosis.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Modern Urology
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS